This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
by Zacks Equity Research
The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
Lilly's (LLY) Jardiance Heart Failure Study Meets Main Goal
by Zacks Equity Research
Lilly's (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Visa, Eli Lilly, Amgen and Sony Group
Top Analyst Reports for Alphabet, Visa & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Visa (V), and Eli Lilly (LLY).
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
by Zacks Equity Research
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Kidney Disease
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of chronic kidney disease in adults with and without type-II diabetes.
AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA
by Zacks Equity Research
The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.
Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status
by Zacks Equity Research
Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
by Zacks Equity Research
Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data
by Kinjel Shah
EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
by Zacks Equity Research
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Here's Why Prothena (PRTA) Stock Is Up So Far This Month
by Zacks Equity Research
Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
by Kinjel Shah
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $222.21, marking a +0.66% move from the previous day.
United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag
by Zacks Equity Research
United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.
AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19
by Zacks Equity Research
AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
by Zacks Equity Research
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
by Kinjel Shah
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.